0000000000810221
AUTHOR
B. González
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…
Epizootic of dolphin morbillivirus on the Catalonian Mediterranean coast in 2007
BETWEEN 1990 and 1992, thousands of striped dolphins (Stenella coeruleoalba) stranded along the Mediterranean coast due to a newly described virus, the dolphin morbillivirus (DMV) (Domingo and others 1990, 1992). DMV is one of the several morbilliviruses that have killed marine mammals worldwide since 1987 (Di Guardo and others 2005). A new DMV epizootic has been recently confirmed from the Mediterranean Spanish and French coasts during 2007 to 2008 (Fernández and others 2008, Raga and others 2008, Keck and others 2010). This short communication describes the pathological findings associated with DMV infection and secondary infections, observed during this epizootic on the Mediterranean coa…